Brain 17 Vienna

WBRT + Temozolomide WBRT +/- temozolomide : • Patients with NSCLC and > 1 newly diagnosed brain metastasis • Poor accrual • WBRT alone: median OS: 5.7 months • WBRT + temozolomide: median OS 4.4 Daily low-dose temozolomide: • Patients with advanced NSCLC; many of them with brain mets • “minimal activity as salvage therapy in patients with advanced NSCLC”

Chua et al. Clin Lung Cancer 2014 Kouroussis et al. Oncology 2009